vs
ANI PHARMACEUTICALS INC（ANIP）与COMPASS MINERALS INTERNATIONAL INC（CMP）财务数据对比。点击上方公司名可切换其他公司
COMPASS MINERALS INTERNATIONAL INC的季度营收约是ANI PHARMACEUTICALS INC的1.6倍（$396.1M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 4.7%，领先6.4%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 28.9%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $-59.8M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 4.3%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
指南针矿产国际是一家美国上市矿产企业，总部位于堪萨斯州欧弗兰帕克，是盐、氯化镁和硫酸钾等产品的领先生产商。公司面向北美和英国客户供应经处理与未经处理的散装道路除冰盐，同时向全球种植者提供植物营养产品，此外也生产民用除冰、水质调节产品及相关商用产品。
ANIP vs CMP — 直观对比
营收规模更大
CMP
是对方的1.6倍
$247.1M
营收增速更快
ANIP
高出0.7%
28.9%
净利率更高
ANIP
高出6.4%
4.7%
自由现金流更多
ANIP
多$88.9M
$-59.8M
两年增速更快
ANIP
近两年复合增速
4.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $396.1M |
| 净利润 | $27.5M | $18.6M |
| 毛利率 | — | 16.0% |
| 营业利润率 | 14.1% | 9.2% |
| 净利率 | 11.1% | 4.7% |
| 营收同比 | 29.6% | 28.9% |
| 净利润同比 | 367.5% | 178.8% |
| 每股收益（稀释后） | $1.14 | $0.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPCMP
| Q4 25 | $247.1M | $396.1M | ||
| Q3 25 | $227.8M | $227.5M | ||
| Q2 25 | $211.4M | $214.6M | ||
| Q1 25 | $197.1M | $494.6M | ||
| Q4 24 | $190.6M | $307.2M | ||
| Q3 24 | $148.3M | $208.8M | ||
| Q2 24 | $138.0M | $202.9M | ||
| Q1 24 | $137.4M | $364.0M |
净利润ANIPCMP
| Q4 25 | $27.5M | $18.6M | ||
| Q3 25 | $26.6M | $-7.2M | ||
| Q2 25 | $8.5M | $-17.0M | ||
| Q1 25 | $15.7M | $-32.0M | ||
| Q4 24 | $-10.3M | $-23.6M | ||
| Q3 24 | $-24.2M | $-48.3M | ||
| Q2 24 | $-2.3M | $-43.6M | ||
| Q1 24 | $18.2M | $-38.9M |
毛利率ANIPCMP
| Q4 25 | — | 16.0% | ||
| Q3 25 | — | 16.9% | ||
| Q2 25 | — | 19.2% | ||
| Q1 25 | — | 15.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | 9.3% | ||
| Q2 24 | — | 16.1% | ||
| Q1 24 | — | 19.7% |
营业利润率ANIPCMP
| Q4 25 | 14.1% | 9.2% | ||
| Q3 25 | 15.9% | 5.3% | ||
| Q2 25 | 6.6% | 7.4% | ||
| Q1 25 | 13.3% | -0.6% | ||
| Q4 24 | -2.3% | 0.2% | ||
| Q3 24 | -13.8% | -14.3% | ||
| Q2 24 | 3.7% | 2.9% | ||
| Q1 24 | 14.8% | -10.8% |
净利率ANIPCMP
| Q4 25 | 11.1% | 4.7% | ||
| Q3 25 | 11.7% | -3.2% | ||
| Q2 25 | 4.0% | -7.9% | ||
| Q1 25 | 8.0% | -6.5% | ||
| Q4 24 | -5.4% | -7.7% | ||
| Q3 24 | -16.3% | -23.1% | ||
| Q2 24 | -1.7% | -21.5% | ||
| Q1 24 | 13.2% | -10.7% |
每股收益（稀释后）ANIPCMP
| Q4 25 | $1.14 | $0.43 | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | $-0.41 | ||
| Q1 25 | $0.69 | $-0.77 | ||
| Q4 24 | $-0.45 | $-0.57 | ||
| Q3 24 | $-1.27 | $-1.17 | ||
| Q2 24 | $-0.14 | $-1.05 | ||
| Q1 24 | $0.82 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $46.7M |
| 总债务越低越好 | — | $890.0M |
| 股东权益账面价值 | $540.7M | $260.5M |
| 总资产 | $1.4B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 3.42× |
8季度趋势，按日历期对齐
现金及短期投资ANIPCMP
| Q4 25 | $285.6M | $46.7M | ||
| Q3 25 | $262.6M | $59.7M | ||
| Q2 25 | $217.8M | $79.4M | ||
| Q1 25 | $149.8M | $49.5M | ||
| Q4 24 | $144.9M | $45.8M | ||
| Q3 24 | $145.0M | $20.2M | ||
| Q2 24 | $240.1M | $12.8M | ||
| Q1 24 | $228.6M | $38.3M |
总债务ANIPCMP
| Q4 25 | — | $890.0M | ||
| Q3 25 | — | $839.8M | ||
| Q2 25 | — | $833.4M | ||
| Q1 25 | — | $807.6M | ||
| Q4 24 | — | $974.4M | ||
| Q3 24 | — | $921.2M | ||
| Q2 24 | — | $875.1M | ||
| Q1 24 | — | $877.2M |
股东权益ANIPCMP
| Q4 25 | $540.7M | $260.5M | ||
| Q3 25 | $505.8M | $234.1M | ||
| Q2 25 | $436.8M | $249.8M | ||
| Q1 25 | $418.6M | $236.5M | ||
| Q4 24 | $403.7M | $263.0M | ||
| Q3 24 | $405.9M | $316.6M | ||
| Q2 24 | $455.8M | $352.1M | ||
| Q1 24 | $452.0M | $400.4M |
总资产ANIPCMP
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.4B | $1.5B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.3B | $1.7B | ||
| Q3 24 | $1.3B | $1.6B | ||
| Q2 24 | $920.8M | $1.6B | ||
| Q1 24 | $914.5M | $1.7B |
负债/权益比ANIPCMP
| Q4 25 | — | 3.42× | ||
| Q3 25 | — | 3.59× | ||
| Q2 25 | — | 3.34× | ||
| Q1 25 | — | 3.41× | ||
| Q4 24 | — | 3.70× | ||
| Q3 24 | — | 2.91× | ||
| Q2 24 | — | 2.49× | ||
| Q1 24 | — | 2.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $-37.0M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $-59.8M |
| 自由现金流率自由现金流/营收 | 11.8% | -15.1% |
| 资本支出强度资本支出/营收 | 0.5% | 5.8% |
| 现金转化率经营现金流/净利润 | 1.10× | -1.99× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $94.1M |
8季度趋势，按日历期对齐
经营现金流ANIPCMP
| Q4 25 | $30.4M | $-37.0M | ||
| Q3 25 | $44.1M | $-6.9M | ||
| Q2 25 | $75.8M | $21.8M | ||
| Q1 25 | $35.0M | $186.9M | ||
| Q4 24 | $15.9M | $-4.1M | ||
| Q3 24 | $12.5M | $-12.7M | ||
| Q2 24 | $17.4M | $-6.8M | ||
| Q1 24 | $18.3M | $86.2M |
自由现金流ANIPCMP
| Q4 25 | $29.1M | $-59.8M | ||
| Q3 25 | $38.0M | $-22.8M | ||
| Q2 25 | $71.8M | $3.8M | ||
| Q1 25 | $32.5M | $172.9M | ||
| Q4 24 | $13.5M | $-25.9M | ||
| Q3 24 | $7.7M | $-33.6M | ||
| Q2 24 | $13.0M | $-21.5M | ||
| Q1 24 | $13.7M | $56.2M |
自由现金流率ANIPCMP
| Q4 25 | 11.8% | -15.1% | ||
| Q3 25 | 16.7% | -10.0% | ||
| Q2 25 | 34.0% | 1.8% | ||
| Q1 25 | 16.5% | 35.0% | ||
| Q4 24 | 7.1% | -8.4% | ||
| Q3 24 | 5.2% | -16.1% | ||
| Q2 24 | 9.4% | -10.6% | ||
| Q1 24 | 10.0% | 15.4% |
资本支出强度ANIPCMP
| Q4 25 | 0.5% | 5.8% | ||
| Q3 25 | 2.7% | 7.0% | ||
| Q2 25 | 1.9% | 8.4% | ||
| Q1 25 | 1.3% | 2.8% | ||
| Q4 24 | 1.3% | 7.1% | ||
| Q3 24 | 3.2% | 10.0% | ||
| Q2 24 | 3.2% | 7.2% | ||
| Q1 24 | 3.3% | 8.2% |
现金转化率ANIPCMP
| Q4 25 | 1.10× | -1.99× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
CMP
| Highway Deicing Salt | $210.8M | 53% |
| Consumer Industrial Salt | $120.7M | 30% |
| Plant Nutrition | $60.8M | 15% |
| Transferred Over Time | $2.8M | 1% |
| Other | $1.0M | 0% |
